154 related articles for article (PubMed ID: 9157988)
21. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
22. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.
Gotoh Y; Suzuki H; Kinoshita S; Hirohashi T; Kato Y; Sugiyama Y
J Pharmacol Exp Ther; 2000 Jan; 292(1):433-9. PubMed ID: 10604980
[TBL] [Abstract][Full Text] [Related]
23. Reduced folate derivatives are endogenous substrates for cMOAT in rats.
Kusuhara H; Han YH; Shimoda M; Kokue E; Suzuki H; Sugiyama Y
Am J Physiol; 1998 Oct; 275(4):G789-96. PubMed ID: 9756510
[TBL] [Abstract][Full Text] [Related]
24. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats.
Masuda M; I'izuka Y; Yamazaki M; Nishigaki R; Kato Y; Ni'inuma K; Suzuki H; Sugiyama Y
Cancer Res; 1997 Aug; 57(16):3506-10. PubMed ID: 9270020
[TBL] [Abstract][Full Text] [Related]
26. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
27. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione.
Paulusma CC; van Geer MA; Evers R; Heijn M; Ottenhoff R; Borst P; Oude Elferink RP
Biochem J; 1999 Mar; 338 ( Pt 2)(Pt 2):393-401. PubMed ID: 10024515
[TBL] [Abstract][Full Text] [Related]
28. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats.
Han YH; Kato Y; Watanabe Y; Terao K; Asoh Y; Sugiyama Y
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):394-400. PubMed ID: 11259322
[TBL] [Abstract][Full Text] [Related]
29. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats.
Hirohashi T; Suzuki H; Ito K; Ogawa K; Kume K; Shimizu T; Sugiyama Y
Mol Pharmacol; 1998 Jun; 53(6):1068-75. PubMed ID: 9614210
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide.
Yamada T; Niinuma K; Lemaire M; Terasaki T; Sugiyama Y
J Pharmacol Exp Ther; 1996 Dec; 279(3):1357-64. PubMed ID: 8968360
[TBL] [Abstract][Full Text] [Related]
31. Effects of organic anions and bile acid conjugates on biliary excretion of LTC4 in the rat.
Kitaura K; Takikawa H; Yamanaka M
Prostaglandins; 1997 Nov; 54(5):745-55. PubMed ID: 9491205
[TBL] [Abstract][Full Text] [Related]
32. Trandolaprilat, an angiotensin-converting enzyme inhibitor, is not excreted in bile via an ATP-dependent active transporter (cMOAT).
Shionoiri H; Takasaki I; Minamisawa K; Ishizuka H; Konno K; Naganuma H; Sasahara K; Kawahara Y
Hypertens Res; 2001 May; 24(3):235-40. PubMed ID: 11409646
[TBL] [Abstract][Full Text] [Related]
33. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats.
Yamazaki M; Kobayashi K; Sugiyama Y
Biopharm Drug Dispos; 1996 Oct; 17(7):607-21. PubMed ID: 8894118
[TBL] [Abstract][Full Text] [Related]
34. Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinaemic rats.
Yamazaki M; Kobayashi K; Sugiyama Y
Biopharm Drug Dispos; 1996 Nov; 17(8):645-59. PubMed ID: 8950045
[TBL] [Abstract][Full Text] [Related]
35. Characterization of secretory intestinal transport of the lactone form of CPT-11.
Takemoto I; Itagaki S; Chiba M; Itoh T; Hirano T; Iseki K
Cancer Chemother Pharmacol; 2006 Jan; 57(1):129-33. PubMed ID: 16003561
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine.
Lokiec F; Canal P; Gay C; Chatelut E; Armand JP; Roché H; Bugat R; Gonçalvès E; Mathieu-Boué A
Cancer Chemother Pharmacol; 1995; 36(1):79-82. PubMed ID: 7720181
[TBL] [Abstract][Full Text] [Related]
37. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat.
Sasabe H; Kato Y; Tsuji A; Sugiyama Y
J Pharmacol Exp Ther; 1998 Feb; 284(2):661-8. PubMed ID: 9454812
[TBL] [Abstract][Full Text] [Related]
38. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
[TBL] [Abstract][Full Text] [Related]
39. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma.
Rivory LP; Robert J
J Chromatogr B Biomed Appl; 1994 Nov; 661(1):133-41. PubMed ID: 7866541
[TBL] [Abstract][Full Text] [Related]
40. Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.
Arimori K; Kuroki N; Kumamoto A; Tanoue N; Nakano M; Kumazawa E; Tohgo A; Kikuchi M
Pharm Res; 2001 Jun; 18(6):814-22. PubMed ID: 11474786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
